The expression and significance of cathepsin L (CTSL) 
Introduction

Chronic myeloid leukaemia (CML) is a clonal disorder in which cells of the myeloid lineage undergo unregulated proliferation. The leukemic cells progressively lose their ability to differentiate as they pass through chronic phase (CP), accelerated phase (AP) and finally blast crisis (BC)
. This disease is characterized by Philadelphia chromosome created due to a reciprocal translocation between the long arms of chromosomes 9 and 22 (t (9; 22) [3] [4] [5] [6] . [7] . Sun et al. [8] [9] [10] [11] [12] . The expression of this protease is also elevated by pro-inflammatory cytokines, oncogenes and tumour promoters [13] [14] [15] [16] [17] . In addition our laboratory has previously demonstrated transcriptional upregulation of CTSL by VEGF in glioblastoma cells [18] . A majority of CTSL synthesized by tumour cell is secreted out for which its intact carboxy terminus is essential [19] . The secreted protease confers invasive ability to the tumour cells. High levels of CTSL have been associated with poor prognosis of meningiomas [20] , non-small cell lung cancer [21] , breast cancer [22] and pancreatic adenocarcinoma [23] . Human CTSL is encoded by multiple mRNA species generated by the alternate splicing of the same primary mRNA transcribed from the single gene located on chromosome 9q [21] [22] [24, 25] . Altered expression of genes located on the long arm of chromosome 9 has been demonstrated in CML [26] . Similarly, the overexpression of VEGF, a transcriptional regulator of CTSL [18] [28] . Then CTSL activity in the cell lysate containing 50 g of total protein was assayed, in the presence of 5 M CA074 (SigmaAldrich), a specific cathepsin B inhibitor as described earlier [29] . The enzymatic activities were expressed as arbitrary units/min./mg protein (AU). (Fig. 1C) .
(q34; q11). The consequence of this signature translocation is the generation of the fusion protein Bcr-Abl, a constitutively activated tyrosine kinase. Several studies have clearly demonstrated that Bcr-Abl is sufficient for causing CML
Possible pathogenic roles of proteases in the progression of leukaemia have long been speculated. Excessive egression of leukemic cells from bone marrow into peripheral blood followed by infiltration of organs is often seen in leukaemia. These movements are supposedly facilitated by proteases due to their capability of catalytic modification of extracellular matrix components. While studying the pathogenesis of CML, it was found that matrix metalloproteases mainly MMP-9 and MMP-2 along with vascular endothelial growth factor (VEGF) stimulate angiogenesis in CML
have reported membrane type 1-MMP (MT1-MMP) as a novel downstream target of Bcr-Abl/Abl signalling. Cathepsin L (CTSL), a lysosomal cysteine protease, primarily responsible for the normal degradation and turnover of intracellular proteins, is overexpressed by malignant tumours
RNA isolation and real-time qPCR
Results
Characteristics of patients and controls
To further confirm the elevated expression of CTSL in CP of CML, representative samples of CML CP, CML AP/BC and NCs were subjected to immuno-blot analysis using a monoclonal antibody. As evident from Figure 1D, Fig. 2A) . Likewise, the VEGF mRNA expression observed in CML CP patients was 7.7-and 9.1-fold higher compared to PCs and NCs, respectively (P Յ 0.001, Fig. 2A ). Though the VEGF mRNA expression was severely compromised in CML AP/BC patients, its expression was 2.1-fold higher in these patients compared to the PCs (P Յ 0.001, Fig. 2A ) and 2.4-fold higher compared to NCs (P Յ 0.001, Fig. 2A (Fig. 2C ). 0.001, Fig. 2D Fig. 2E ). 
Treatment of PBMCs isolated from NCs with recombinant VEGF resulted in a statistically significant 1.92-fold increase (P ϭ 0.02) in CTSL activity thereby confirming the role of this growth factor in elevating CTSL expression. However, only a marginal increase in the activity of this protease was observed when PBMCs isolated from CML CP patients were treated VEGF
Cystatin C expression and its correlation with CTSL activity
There was no significant difference in the expression of cystatin C in CP and AP/BC phases of CML. Its expression was significantly elevated in the controls with NCs exhibiting 5.3-and 5.6-fold
001, Mann-Whitney U-test). (B) Correlation of VEGF with CTSL mRNA in the CML cohort. (Pearson correlation analysis) (C) Increase in CTSL activity by exogenous VEGF. PBMCs isolated from CML CP and NCs were seeded (80% confluent) in six-well plates followed by serum starvation for 12 hrs. Then 40 ng/ml of recombinant VEGF 165 was added to these cells in fresh serum free RPMI 1640 containing 0.1% bovine serum albumin. After 48 hrs of VEGF treatment, cells were lysed and CTSL activity in the lysates was measured as described in 'Materials and methods'. PBMCs treated with PBS were processed identically and served as controls. Values presented are mean Ϯ S.E. from four independent estimations. Results were analysed by Student's t-test and values significantly different from respective controls have been marked by 'a'. (D) Relative abundance of cystatin C mRNA in CML patients and controls; (a) significantly lower compared to PCs; (b) significantly lower compared to NC (P Յ 0.001, Mann-Whitney U-test). (E) Correlation of cystatin C mRNA with CTSL activity in the CML cohort (Pearson correlation analysis). higher values compared to CML CP and CML AP/BC patients, respectively (P Յ 0.001, Fig. 2C). Similarly, the cystatin C mRNA expression in PCs was 5.0-and 5.3-fold higher compared to CML CP and CML AP/BC patients, respectively (P Յ
Association of Bcr-Abl with the expression of VEGF and CTSL mRNA in CML patients
Role of promoter methylation in CTSL expression in various phases of CML
Jean et al. [31] reported the presence of a CpG island containing 40 CpG sites in 650 bp of CTSL promoter region proximal to the transcription initiation site and established the role of promoter
Fig. 3 Bcr-Abl expression and its correlation with VEGF as well as CTSL. Correlation between Bcr-Abl and (A) VEGF or (B) CTSL mRNA expression in CML CP patients. Pearson correlation coefficient (r) indicated a strong positive association of Bcr-Abl with VEGF (A) as well as CTSL mRNA (B) expression in CML CP patients. Correlation between Bcr-Abl and (C) VEGF (D) CTSL mRNA expression in CML AP/BC patients. Pearson correlation coefficient (r) indicated no association of Bcr-Abl with VEGF (C) or CTSL (D) in CML AP/BC patients. methylation in regulating CTSL expression in melanoma cells. In an effort to understand the role of promoter methylation in phasespecific expression of CTSL in CML, we analysed the methylation status of half of these sites.
As summarized in Figure 4, (Fig. 1A and B ) also exhibited hypermethylation of CTSL promoter. Figure 4 , 10 sites were methylated in K562 which is comparable to the average methylated sites (9 Ϯ 0.52; mean Ϯ (Fig. 5A) . However, no such increase in the levels of cystatin C mRNA or 18S RNA was observed in these cells at any time during the course of treatment with 5Ј-aza-cytidine (Fig. 5A) . The observed increase in CTSL mRNA levels after this treatment in K562 cells was further corroborated by a noticeable increase in immuno-reactive 26 kD enzymatically active form of CTSL detected by immuno-blotting (Fig. 5B) .Under the same conditions, ␣-tubulin protein (control) was not altered by the 5Ј-aza-cytidine treatment (bottom line of Fig. 5B ). Quantitative real-time PCR analysis revealed a significant (2.6-fold) increase (P Յ 0.05) in CTSL mRNA expression at 72 hrs (Fig. 5C) . This was associated with a parallel increase (2.8-fold increase, P Յ 0.05, Student's t-test) in CTSL activity (Fig. 5D) .
As depicted in
S.E.) in CML AP/BC patients. Treatment of K562 cells with 5Ј-azacytidine (a known inhibitor of DNA methyl transferase) resulted in a time dependent increase in the levels of CTSL mRNA
The role of promoter hyper-methylation in decreasing CTSL expression in CML AP/BC was further corroborated by treating PBMCs isolated from these patients with 5Ј-aza-cytidine. As evident from Figure 5E , aza-cytidine treated PBMCs from these patients exhibited higher levels of immuno-reactive CTSL as compared to their untreated counterparts. After this treatment the levels of CTSL in AP/BC PBMCs was found to be comparable to that observed in CML CP patients (Fig. 5E ).
Discussion
Elevated expression of CTSL has been reported in a number of human tumours [9, 12] 
